Shree Ganesh Remedies Ltd
Shree Ganesh Remedies is engaged in the business of Pharma Intermediate.
- Market Cap ₹ 809 Cr.
- Current Price ₹ 631
- High / Low ₹ 736 / 282
- Stock P/E 36.8
- Book Value ₹ 77.9
- Dividend Yield 0.08 %
- ROCE 24.7 %
- ROE 22.6 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 29.7% CAGR over last 5 years
- Company's median sales growth is 27.3% of last 10 years
Cons
- Stock is trading at 8.10 times its book value
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
15 | 13 | 18 | 16 | 16 | 20 | 27 | 35 | 58 | 49 | 71 | 90 | 117 | |
13 | 10 | 14 | 14 | 14 | 16 | 22 | 26 | 47 | 35 | 53 | 67 | 85 | |
Operating Profit | 3 | 2 | 5 | 2 | 2 | 4 | 5 | 9 | 11 | 14 | 18 | 23 | 32 |
OPM % | 17% | 19% | 25% | 13% | 12% | 21% | 19% | 25% | 19% | 28% | 25% | 26% | 28% |
0 | 1 | 1 | 0 | 0 | 0 | 2 | 1 | 4 | 2 | 4 | 3 | 3 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 4 | 5 |
Profit before tax | 2 | 2 | 5 | 2 | 2 | 4 | 6 | 9 | 13 | 13 | 18 | 23 | 30 |
Tax % | 32% | 33% | 32% | 33% | 34% | 33% | 28% | 28% | 24% | 25% | 26% | 25% | |
2 | 1 | 3 | 1 | 1 | 3 | 5 | 6 | 10 | 10 | 13 | 17 | 22 | |
EPS in Rs | 9.94 | 9.25 | 20.06 | 7.94 | 6.75 | 16.50 | 3.66 | 4.88 | 7.52 | 7.62 | 10.47 | 13.30 | 17.17 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 19% | 18% | 14% | 18% | 4% | 2% |
Compounded Sales Growth | |
---|---|
10 Years: | 22% |
5 Years: | 27% |
3 Years: | 16% |
TTM: | 44% |
Compounded Profit Growth | |
---|---|
10 Years: | 28% |
5 Years: | 30% |
3 Years: | 21% |
TTM: | 46% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 70% |
3 Years: | 34% |
1 Year: | 114% |
Return on Equity | |
---|---|
10 Years: | 22% |
5 Years: | 23% |
3 Years: | 23% |
Last Year: | 23% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 10 | 12 | 13 | 13 |
Reserves | 6 | 7 | 11 | 12 | 13 | 15 | 20 | 25 | 33 | 40 | 50 | 76 | 87 |
3 | 2 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 0 | 0 | 34 | 38 | |
3 | 2 | 2 | 2 | 2 | 5 | 5 | 7 | 8 | 10 | 15 | 21 | 18 | |
Total Liabilities | 12 | 12 | 15 | 15 | 16 | 21 | 36 | 41 | 52 | 61 | 77 | 144 | 156 |
4 | 4 | 4 | 4 | 4 | 4 | 6 | 14 | 16 | 19 | 27 | 36 | 82 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 42 | 5 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 7 | 3 | 0 | 0 | 5 |
8 | 8 | 10 | 11 | 11 | 17 | 25 | 23 | 29 | 37 | 47 | 66 | 64 | |
Total Assets | 12 | 12 | 15 | 15 | 16 | 21 | 36 | 41 | 52 | 61 | 77 | 144 | 156 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 1 | 5 | -1 | -2 | 2 | -1 | -5 | 4 | 3 | 13 | 17 | |
0 | 0 | -1 | 1 | 1 | 0 | -3 | -0 | -3 | -1 | -12 | -54 | |
0 | -1 | -0 | -0 | -0 | -0 | 8 | -0 | -0 | -1 | -1 | 41 | |
Net Cash Flow | 0 | 0 | 3 | -1 | -0 | 2 | 4 | -5 | 1 | 2 | 0 | 5 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 106 | 100 | 45 | 93 | 133 | 136 | 78 | 101 | 104 | 99 | 94 | 113 |
Inventory Days | 86 | 186 | 126 | 132 | 130 | 103 | 102 | 125 | 56 | 206 | 132 | 138 |
Days Payable | 44 | 47 | 23 | 43 | 32 | 90 | 43 | 75 | 39 | 101 | 92 | 111 |
Cash Conversion Cycle | 148 | 239 | 149 | 183 | 232 | 149 | 137 | 151 | 120 | 205 | 134 | 141 |
Working Capital Days | 136 | 187 | 96 | 160 | 202 | 172 | 156 | 149 | 115 | 159 | 133 | 129 |
ROCE % | 31% | 25% | 44% | 16% | 12% | 26% | 27% | 27% | 33% | 28% | 33% | 25% |
Documents
Announcements
- Commencement Of Trial Run. 17 Apr
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 5 Apr
- Certificate Under Regulation 40 (9) Of SEBI (LODR) Regulations, 2015 For Year Ended On March 31, 2024. 5 Apr
- Compliance Certificate Pursuant To Regulation 7 (3) Of SEBI (LODR) Regulations, 2015 For The Year Ended On March 31, 2024 5 Apr
- Closure of Trading Window 26 Mar
Business segments[1]
Pharmaceutical intermediates: 32+ products; 54 Cr sales in FY23 (vs 51 Cr in FY22)
Human pharma segments: Antipsychotic, Antidepression, Oncology, Diabetic, Diuretic
Veterinary segment: Feed Additives, Antiparasitic, Anti-Inflammator
Fine and Specialty Chemicals: 11+ products; 37 Cr. sales in FY23 (vs 20 Cr. in FY22)
Industries served: Aroma & Health, Agrochem, Polymer, Electronics